JP2024516698A - Ｉｌｔ７結合タンパク質を使用する、自己免疫疾患の治療方法 - Google Patents

Ｉｌｔ７結合タンパク質を使用する、自己免疫疾患の治療方法 Download PDF

Info

Publication number
JP2024516698A
JP2024516698A JP2023567897A JP2023567897A JP2024516698A JP 2024516698 A JP2024516698 A JP 2024516698A JP 2023567897 A JP2023567897 A JP 2023567897A JP 2023567897 A JP2023567897 A JP 2023567897A JP 2024516698 A JP2024516698 A JP 2024516698A
Authority
JP
Japan
Prior art keywords
binding protein
subject
ilt7
weeks
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023567897A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516698A5 (enExample
Inventor
ウィリアム リース
ガボール イレイ
リ ヤン
ジョーン ドラッパ
ジョン ラッチフォード
エドワード ハモンド
Original Assignee
ビエラ バイオ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビエラ バイオ インコーポレイテッド filed Critical ビエラ バイオ インコーポレイテッド
Publication of JP2024516698A publication Critical patent/JP2024516698A/ja
Publication of JP2024516698A5 publication Critical patent/JP2024516698A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2023567897A 2021-05-04 2022-05-04 Ｉｌｔ７結合タンパク質を使用する、自己免疫疾患の治療方法 Pending JP2024516698A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163183886P 2021-05-04 2021-05-04
US63/183,886 2021-05-04
US202163197789P 2021-06-07 2021-06-07
US63/197,789 2021-06-07
US202163242768P 2021-09-10 2021-09-10
US63/242,768 2021-09-10
US202163249953P 2021-09-29 2021-09-29
US63/249,953 2021-09-29
US202263326424P 2022-04-01 2022-04-01
US63/326,424 2022-04-01
PCT/US2022/027620 WO2022235758A1 (en) 2021-05-04 2022-05-04 Methods of treatment of autoimmune disorders using ilt7 binding proteins

Publications (2)

Publication Number Publication Date
JP2024516698A true JP2024516698A (ja) 2024-04-16
JP2024516698A5 JP2024516698A5 (enExample) 2025-05-13

Family

ID=82021082

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023567897A Pending JP2024516698A (ja) 2021-05-04 2022-05-04 Ｉｌｔ７結合タンパク質を使用する、自己免疫疾患の治療方法

Country Status (10)

Country Link
US (1) US20240287176A1 (enExample)
EP (1) EP4333877A1 (enExample)
JP (1) JP2024516698A (enExample)
KR (1) KR20240004451A (enExample)
AU (1) AU2022270101A1 (enExample)
BR (1) BR112023023036A2 (enExample)
CA (1) CA3217278A1 (enExample)
IL (1) IL308132A (enExample)
MX (1) MX2023013015A (enExample)
WO (1) WO2022235758A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6979976B2 (ja) 2016-03-10 2021-12-15 ヴィエラ バイオ，インコーポレーテッド Ｉｌｔ７結合分子及びその使用方法
WO2021203013A2 (en) 2020-04-03 2021-10-07 Viela Bio, Inc. Methods of treating immune mediated pulmonary injury
WO2024026388A1 (en) * 2022-07-27 2024-02-01 Viela Bio, Inc. Formulations comprising an immunoglobulin-like transcript 7 (ilt7)-binding protein
CN120076802A (zh) * 2022-09-30 2025-05-30 艾伯维公司 治疗化脓性汗腺炎的方法
JP2025540348A (ja) * 2022-12-12 2025-12-11 ビエラ バイオ インコーポレイテッド 筋炎の処置及び予防のための、抗ｉｌｔ７結合剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019516392A (ja) * 2016-03-10 2019-06-20 ヴィエラ バイオ，インコーポレーテッド Ｉｌｔ７結合分子及びその使用方法
WO2020084591A1 (en) * 2018-10-26 2020-04-30 Janssen Biotech, Inc. Type i interferon signatures and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1964852T1 (sl) * 2005-12-20 2013-09-30 Sbi Biotech Co. Ltd. Proti-ilt7 protitelo
WO2010065536A2 (en) * 2008-12-01 2010-06-10 The Board Of Regents Of The University Of Texas System Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases
SMT201700063T1 (it) * 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1
IL293572A (en) 2019-12-06 2022-08-01 Viela Bio Inc Treatment methods using ilt7 binding proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019516392A (ja) * 2016-03-10 2019-06-20 ヴィエラ バイオ，インコーポレーテッド Ｉｌｔ７結合分子及びその使用方法
WO2020084591A1 (en) * 2018-10-26 2020-04-30 Janssen Biotech, Inc. Type i interferon signatures and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ARTHRITIS RHEUMATOL., vol. 72, JPN6026018525, 2020, pages 10, ISSN: 0005853660 *

Also Published As

Publication number Publication date
MX2023013015A (es) 2023-11-15
AU2022270101A1 (en) 2023-10-05
CA3217278A1 (en) 2022-11-10
US20240287176A1 (en) 2024-08-29
EP4333877A1 (en) 2024-03-13
BR112023023036A2 (pt) 2024-01-23
WO2022235758A1 (en) 2022-11-10
IL308132A (en) 2023-12-01
KR20240004451A (ko) 2024-01-11

Similar Documents

Publication Publication Date Title
US20240287176A1 (en) Methods of treatment of autoimmune disorders using ilt7 binding proteins
JP7564347B2 (ja) 多発性硬化症を治療するためのｌｏｕ０６４
KR20150048887A (ko) Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법
US20220403020A1 (en) Methods of treatment using ilt7 binding proteins
US20240059783A1 (en) Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders
WO2022075476A1 (en) Method for treating ox40 related disease
JP2024542148A (ja) ヒト化抗ｃｄ４０抗体の医薬組成物およびその使用
JP2022028788A (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
US20240368294A1 (en) Cd40l-specific tn3-derived scaffolds for use in the treatment and prevention of rheumatoid arthritis
EP4634225A1 (en) Anti-ilt7 binding agents for the treatment and prevention of myositis
WO2024152001A1 (en) Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjögren's syndrome
CN117561076A (zh) 使用ilt7结合蛋白治疗自体免疫病症的方法
TW202319067A (zh) 異位性皮膚炎之治療
RU2845151C1 (ru) Способы лечения с использованием ilt7-связывающих белков
RU2858696C2 (ru) Способы лечения первично-прогрессирующего рассеянного склероза с применением ингибитора тирозинкиназы брутона
EP3952993B1 (en) Method of treating fumaric acid ester-resistant plaque psoriasis
KR20250135238A (ko) 면역 매개 괴사성 근병증의 치료 및 예방을 위한 항-cd19 결합제
HK40113661A (en) Cd40l-specific tn3-derived scaffolds for use in the treatment and prevention of rheumatoid arthritis
TW202539688A (zh) 使用索樂匹尼布處置溫型自體免疫性溶血性貧血的方法
CN119630422A (zh) 使用白细胞介素-17(il-17)拮抗剂治疗巨细胞动脉炎的方法
JP2024516019A (ja) 抗ｂａｆｆｒ抗体を使用する全身性エリテマトーデスのための治療
CN118076369A (zh) Cd40l特异性tn3衍生支架及其用于治疗和预防类风湿性关节炎的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250501

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260508

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260804

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260807